Search

Your search keyword '"Hahn, Noah M."' showing total 634 results
Start Over Author "Hahn, Noah M."
634 results on '"Hahn, Noah M."'

1. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy

Author

Grivas, Petros, Koshkin, Vadim S., Chu, Xiangying, Cole, Suzanne, Jain, Rohit K., Dreicer, Robert, Cetnar, Jeremy P., Sundi, Debasish, Gartrell, Benjamin A., Galsky, Matthew D., Woo, Brianna, Li-Ning-Tapia, Elsa, Hahn, Noah M., and Carducci, Michael A.

Published
2024
Full Text
View/download PDF

6. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

Author

Hahn, Noah M., O'Donnell, Michael A., Efstathiou, Jason A., Zahurak, Marianna, Rosner, Gary L., Smith, Jeff, Kates, Max R., Bivalacqua, Trinity J., Tran, Phuoc T., Song, Daniel Y., Baras, Alex S., Matoso, Andres, Choi, Woonyoung, Smith, Kellie N., Pardoll, Drew M., Marchionni, Luigi, McGuire, Bridget, Grace Phelan, Mary, Johnson, Burles A., III, O'Neal, Tanya, McConkey, David J., Rose, Tracy L., Bjurlin, Marc, Lim, Emerson A., Drake, Charles G., McKiernan, James M., Deutsch, Israel, Anderson, Christopher B., Lamm, Donald L., Geynisman, Daniel M., Plimack, Elizabeth R., Hallman, Mark A., Horwitz, Eric M., Al-Saleem, Essel, Chen, David Y.T., Greenberg, Richard E., Kutikov, Alexander, Guo, Gordon, Masterson, Timothy A., Adra, Nabil, and Kaimakliotis, Hristos Z.

Published
2023
Full Text
View/download PDF

9. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer – Clinical Activity and Whole Transcriptome Analysis

Author

Johnson III, Burles A., primary, Teply, Benjamin A., additional, Kagemann, Catherine, additional, McGuire, Bridget, additional, Lombardo, Kara, additional, Jing, Yuezhou, additional, Langbo, William, additional, Epstein, Jonathan I., additional, Netto, George J., additional, Baras, Alex S., additional, Matoso, Andres, additional, McConkey, David J., additional, Gupta, Amol, additional, Ahuja, Nita, additional, Ross, Ashley E., additional, Pierorazio, Phillip M., additional, Comperat, Eva, additional, Hoffman-Censits, Jean, additional, Singla, Nirmish, additional, Patel, Sunil H., additional, Kates, Max, additional, Choi, Woonyoung, additional, Bivalacqua, Trinity J., additional, and Hahn, Noah M., additional

Published
2024
Full Text
View/download PDF

16. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy

Author

Grivas, Petros, primary, Koshkin, Vadim S., additional, Chu, Xiangying, additional, Cole, Suzanne, additional, Jain, Rohit K., additional, Dreicer, Robert, additional, Cetnar, Jeremy P., additional, Sundi, Debasish, additional, Gartrell, Benjamin A., additional, Galsky, Matthew D., additional, Woo, Brianna, additional, Li-Ning-Tapia, Elsa, additional, Hahn, Noah M., additional, and Carducci, Michael A., additional

Published
2023
Full Text
View/download PDF

23. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.

Author

Hoffman-Censits, Jean, Grivas, Petros, Powles, Thomas, Hawley, Jessica, Tyroller, Karin, Seeberger, Sonja, Guenther, Silke, Jacob, Natalia, Mehr, Keyvan Tadjalli, and Hahn, Noah M

Abstract

Results from JAVELIN Bladder 100 established avelumab (anti–PD-L1) first-line maintenance as the standard-of-care treatment for patients with advanced urothelial carcinoma (UC) that has not progressed with first-line platinum-based chemotherapy. We describe the design of JAVELIN Bladder Medley (NCT05327530), an ongoing phase II, multicenter, randomized, open-label, parallel-arm, umbrella trial. Overall, 252 patients with advanced UC who are progression-free following first-line platinum-based chemotherapy will be randomized 1:2:2:2 to receive maintenance therapy with avelumab alone (control group) or combined with sacituzumab govitecan (anti–Trop-2/topoisomerase inhibitor conjugate), M6223 (anti-TIGIT) or NKTR-255 (recombinant human IL-15). Primary end points are progression-free survival per investigator and safety/tolerability of the combination regimens. Secondary end points include overall survival, objective response and duration of response per investigator, and pharmacokinetics. Urothelial cancer develops in the urinary tract, which contains the parts of the body that move urine from the kidneys to outside of the body. Urothelial cancer is called advanced when it has spread outside of the urinary tract. Chemotherapy is often the first main treatment given to people with advanced urothelial cancer. Avelumab is an immunotherapy drug that can help the body's immune system find and destroy cancer cells. Results from a trial called JAVELIN Bladder 100 looked at avelumab maintenance treatment, which is given after chemotherapy. The trial showed that avelumab maintenance treatment helped people with advanced urothelial cancer live longer than people who were not treated with avelumab. Avelumab also helped people have a longer time without their cancer getting worse. Avelumab is the only approved maintenance treatment available for people with advanced urothelial cancer that has not worsened after chemotherapy. The JAVELIN Bladder Medley trial will assess whether avelumab maintenance treatment given in combination with other anticancer drugs can help people with advanced urothelial cancer live longer and have a longer time without their cancer getting worse compared with avelumab alone. Researchers will also look at the side effects people have when they receive avelumab alone or combined with the other anticancer drugs in this trial. Results will show whether the benefit of avelumab maintenance treatment can be improved by combining avelumab with other anticancer drugs. People started joining this trial in August 2022. Results will be reported in the future. Clinical Trial Registration: NCT05327530 (ClinicalTrials.gov) Recruiting! JAVELIN Bladder Medley: a phase II umbrella trial exploring novel combinations with avelumab as #1LMaintenanceTherapy for advanced #UrothelialCarcinoma after 1L chemotherapy (NCT05327530). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

Author

Chang, Elaine, primary, Hahn, Noah M., additional, Lerner, Seth P., additional, Fallah, Jaleh, additional, Agrawal, Sundeep, additional, Kamat, Ashish M., additional, Bhatnagar, Vishal, additional, Svatek, Robert S., additional, Jaigirdar, Adnan A., additional, Bross, Peter, additional, Shore, Neal, additional, Kates, Max, additional, Sachse, Karen, additional, Brewer, Jamie R., additional, O’Donnell, Michael A., additional, Steinberg, Gary D., additional, Viviano, Charles J., additional, Bloomquist, Erik, additional, Ribal, Maria J., additional, Galsky, Matthew D., additional, Oliver, Richard, additional, Black, Peter C., additional, Al-Ahmadie, Hikmat, additional, Brothers, Kenneth, additional, Pohar, Kamal, additional, Dinney, Colin P., additional, Feng, Zhou, additional, Downs, Tracy M., additional, Porten, Sima P., additional, Smith, Angela B., additional, Bangs, Rick, additional, Psutka, Sarah P., additional, Agarwal, Neeraj, additional, Amiri-Kordestani, Laleh, additional, Suzman, Daniel L., additional, Pazdur, Richard, additional, Kluetz, Paul G., additional, and Weinstock, Chana, additional

Published
2023
Full Text
View/download PDF

25. Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer

Author

Anker, Jonathan, primary, Pal, Sumanta K, additional, Kim-Schulze, Seunghee, additional, Wang, Huan, additional, Halperin, Rebecca, additional, Uzilov, Andrew, additional, Imai, Naoko, additional, Eikawa, Shingo, additional, Saito, Takuro, additional, Sebra, Robert, additional, Hahn, Noah M, additional, Patel, Manishkumar, additional, Qi, Jingjing, additional, Xie, Hui, additional, Bhardwaj, Nina, additional, Gnjatic, Sacha, additional, and Galsky, Matthew D, additional

Published
2023
Full Text
View/download PDF

31. Figure S7 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Author

Jang, H. Josh, primary, Hostetter, Galen, primary, Macfarlane, Alexander W., primary, Madaj, Zachary, primary, Ross, Eric A., primary, Hinoue, Toshinori, primary, Kulchycki, Justin R., primary, Burgos, Ryan S., primary, Tafseer, Mahvish, primary, Alpaugh, R. Katherine, primary, Schwebel, Candice L., primary, Kokate, Rutika, primary, Geynisman, Daniel M., primary, Zibelman, Matthew R., primary, Ghatalia, Pooja, primary, Nichols, Peter W., primary, Chung, Woonbok, primary, Madzo, Jozef, primary, Hahn, Noah M., primary, Quinn, David I., primary, Issa, Jean-Pierre J., primary, Topper, Michael J., primary, Baylin, Stephen B., primary, Shen, Hui, primary, Campbell, Kerry S., primary, Jones, Peter A., primary, and Plimack, Elizabeth R., primary

Published
2023
Full Text
View/download PDF

32. Cover Image

Author

Parimi, Vamsi, primary, Choi, Woonyoung, additional, Feng, Mingxiao, additional, Fong, Megan, additional, Hoffman‐Censits, Jean, additional, Kates, Max, additional, Lombardo, Kara A., additional, Comperat, Eva, additional, McConkey, David J., additional, Hahn, Noah M., additional, Esteves, Rodrigo Salgado, additional, and Matoso, Andres, additional

Published
2023
Full Text
View/download PDF

33. Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy

Author

Thomas, Derek E., Kaimakliotis, Hristos Z., Rice, Kevin R., Pereira, Jose A., Johnston, Paul, Moore, Marietta L., Reed, Angela, Cregar, Dylan M., Franklin, Cindy, Loman, Rhoda L., Koch, Michael O., Bihrle, Richard, Foster, Richard S., Masterson, Timothy A., Gardner, Thomas A., Sundaram, Chandru P., Powell, Charles R., Beck, Stephen D.W., Grignon, David J., Cheng, Liang, Albany, Costantine, and Hahn, Noah M.

Published
2017
Full Text
View/download PDF

34. Bladder cancer

Author

Kamat, Ashish M, Hahn, Noah M, Efstathiou, Jason A, Lerner, Seth P, Malmström, Per-Uno, Choi, Woonyoung, Guo, Charles C, Lotan, Yair, and Kassouf, Wassim

Published
2016
Full Text
View/download PDF

36. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)

Author

Rosenberg, Jonathan E., Hahn, Noah M., Regan, Meredith M., Werner, Lillian, Alva, Ajjai, George, Saby, Picus, Joel, Alter, Robert, Balar, Arjun, Hoffman-Censits, Jean, Grivas, Petros, Lauer, Richard, Guancial, Elizabeth A., Hoimes, Christopher, Sonpavde, Guru, Albany, Constantine, Stein, Mark N., Breen, Tim, Jacobs, Cindy, Anderson, Kirsten, Bellmunt, Joaquim, Lalani, Aly-Khan A., Pal, Sumanta, and Choueiri, Toni K.

Published
2018
Full Text
View/download PDF

37. Data from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Author

Jang, H. Josh, primary, Hostetter, Galen, primary, Macfarlane, Alexander W., primary, Madaj, Zachary, primary, Ross, Eric A., primary, Hinoue, Toshinori, primary, Kulchycki, Justin R., primary, Burgos, Ryan S., primary, Tafseer, Mahvish, primary, Alpaugh, R. Katherine, primary, Schwebel, Candice L., primary, Kokate, Rutika, primary, Geynisman, Daniel M., primary, Zibelman, Matthew R., primary, Ghatalia, Pooja, primary, Nichols, Peter W., primary, Chung, Woonbok, primary, Madzo, Jozef, primary, Hahn, Noah M., primary, Quinn, David I., primary, Issa, Jean-Pierre J., primary, Topper, Michael J., primary, Baylin, Stephen B., primary, Shen, Hui, primary, Campbell, Kerry S., primary, Jones, Peter A., primary, and Plimack, Elizabeth R., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Author

Jang, H. Josh, primary, Hostetter, Galen, primary, Macfarlane, Alexander W., primary, Madaj, Zachary, primary, Ross, Eric A., primary, Hinoue, Toshinori, primary, Kulchycki, Justin R., primary, Burgos, Ryan S., primary, Tafseer, Mahvish, primary, Alpaugh, R. Katherine, primary, Schwebel, Candice L., primary, Kokate, Rutika, primary, Geynisman, Daniel M., primary, Zibelman, Matthew R., primary, Ghatalia, Pooja, primary, Nichols, Peter W., primary, Chung, Woonbok, primary, Madzo, Jozef, primary, Hahn, Noah M., primary, Quinn, David I., primary, Issa, Jean-Pierre J., primary, Topper, Michael J., primary, Baylin, Stephen B., primary, Shen, Hui, primary, Campbell, Kerry S., primary, Jones, Peter A., primary, and Plimack, Elizabeth R., primary

Published
2023
Full Text
View/download PDF

40. Supp Figure 4 from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

Author

Michailidi, Christina, primary, Hayashi, Masamichi, primary, Datta, Sayantan, primary, Sen, Tanusree, primary, Zenner, Kaitlyn, primary, Oladeru, Oluwadamilola, primary, Brait, Mariana, primary, Izumchenko, Evgeny, primary, Baras, Alexander, primary, VandenBussche, Christopher, primary, Argos, Maria, primary, Bivalacqua, Trinity J., primary, Ahsan, Habibul, primary, Hahn, Noah M., primary, Netto, George J., primary, Sidransky, David, primary, and Hoque, Mohammad Obaidul, primary

Published
2023
Full Text
View/download PDF

41. Data from Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer

Author

Kates, Max, primary, Nirschl, Thomas, primary, Sopko, Nikolai A., primary, Matsui, Hotaka, primary, Kochel, Christina M., primary, Reis, Leonardo O., primary, Netto, George J., primary, Hoque, Mohammad O., primary, Hahn, Noah M., primary, McConkey, David J., primary, Baras, Alex S., primary, Drake, Charles G., primary, and Bivalacqua, Trinity J., primary

Published
2023
Full Text
View/download PDF

42. Supp Figure 1 from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

Author

Michailidi, Christina, primary, Hayashi, Masamichi, primary, Datta, Sayantan, primary, Sen, Tanusree, primary, Zenner, Kaitlyn, primary, Oladeru, Oluwadamilola, primary, Brait, Mariana, primary, Izumchenko, Evgeny, primary, Baras, Alexander, primary, VandenBussche, Christopher, primary, Argos, Maria, primary, Bivalacqua, Trinity J., primary, Ahsan, Habibul, primary, Hahn, Noah M., primary, Netto, George J., primary, Sidransky, David, primary, and Hoque, Mohammad Obaidul, primary

Published
2023
Full Text
View/download PDF

43. Supp Figure 3 from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

Author

Michailidi, Christina, primary, Hayashi, Masamichi, primary, Datta, Sayantan, primary, Sen, Tanusree, primary, Zenner, Kaitlyn, primary, Oladeru, Oluwadamilola, primary, Brait, Mariana, primary, Izumchenko, Evgeny, primary, Baras, Alexander, primary, VandenBussche, Christopher, primary, Argos, Maria, primary, Bivalacqua, Trinity J., primary, Ahsan, Habibul, primary, Hahn, Noah M., primary, Netto, George J., primary, Sidransky, David, primary, and Hoque, Mohammad Obaidul, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 3 from Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer

Author

Kates, Max, primary, Nirschl, Thomas, primary, Sopko, Nikolai A., primary, Matsui, Hotaka, primary, Kochel, Christina M., primary, Reis, Leonardo O., primary, Netto, George J., primary, Hoque, Mohammad O., primary, Hahn, Noah M., primary, McConkey, David J., primary, Baras, Alex S., primary, Drake, Charles G., primary, and Bivalacqua, Trinity J., primary

Published
2023
Full Text
View/download PDF

45. Supp Figure legends from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

Author

Michailidi, Christina, primary, Hayashi, Masamichi, primary, Datta, Sayantan, primary, Sen, Tanusree, primary, Zenner, Kaitlyn, primary, Oladeru, Oluwadamilola, primary, Brait, Mariana, primary, Izumchenko, Evgeny, primary, Baras, Alexander, primary, VandenBussche, Christopher, primary, Argos, Maria, primary, Bivalacqua, Trinity J., primary, Ahsan, Habibul, primary, Hahn, Noah M., primary, Netto, George J., primary, Sidransky, David, primary, and Hoque, Mohammad Obaidul, primary

Published
2023
Full Text
View/download PDF

46. Supp Figure 3 continued from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

Author

Michailidi, Christina, primary, Hayashi, Masamichi, primary, Datta, Sayantan, primary, Sen, Tanusree, primary, Zenner, Kaitlyn, primary, Oladeru, Oluwadamilola, primary, Brait, Mariana, primary, Izumchenko, Evgeny, primary, Baras, Alexander, primary, VandenBussche, Christopher, primary, Argos, Maria, primary, Bivalacqua, Trinity J., primary, Ahsan, Habibul, primary, Hahn, Noah M., primary, Netto, George J., primary, Sidransky, David, primary, and Hoque, Mohammad Obaidul, primary

Published
2023
Full Text
View/download PDF

47. Supp Figure 2A from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

Author

Michailidi, Christina, primary, Hayashi, Masamichi, primary, Datta, Sayantan, primary, Sen, Tanusree, primary, Zenner, Kaitlyn, primary, Oladeru, Oluwadamilola, primary, Brait, Mariana, primary, Izumchenko, Evgeny, primary, Baras, Alexander, primary, VandenBussche, Christopher, primary, Argos, Maria, primary, Bivalacqua, Trinity J., primary, Ahsan, Habibul, primary, Hahn, Noah M., primary, Netto, George J., primary, Sidransky, David, primary, and Hoque, Mohammad Obaidul, primary

Published
2023
Full Text
View/download PDF

48. Supp Table 1, Supp Table 2 from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

Author

Michailidi, Christina, primary, Hayashi, Masamichi, primary, Datta, Sayantan, primary, Sen, Tanusree, primary, Zenner, Kaitlyn, primary, Oladeru, Oluwadamilola, primary, Brait, Mariana, primary, Izumchenko, Evgeny, primary, Baras, Alexander, primary, VandenBussche, Christopher, primary, Argos, Maria, primary, Bivalacqua, Trinity J., primary, Ahsan, Habibul, primary, Hahn, Noah M., primary, Netto, George J., primary, Sidransky, David, primary, and Hoque, Mohammad Obaidul, primary

Published
2023
Full Text
View/download PDF

49. Data from Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

Author

Michailidi, Christina, primary, Hayashi, Masamichi, primary, Datta, Sayantan, primary, Sen, Tanusree, primary, Zenner, Kaitlyn, primary, Oladeru, Oluwadamilola, primary, Brait, Mariana, primary, Izumchenko, Evgeny, primary, Baras, Alexander, primary, VandenBussche, Christopher, primary, Argos, Maria, primary, Bivalacqua, Trinity J., primary, Ahsan, Habibul, primary, Hahn, Noah M., primary, Netto, George J., primary, Sidransky, David, primary, and Hoque, Mohammad Obaidul, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 1 from Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer

Author

Kates, Max, primary, Nirschl, Thomas, primary, Sopko, Nikolai A., primary, Matsui, Hotaka, primary, Kochel, Christina M., primary, Reis, Leonardo O., primary, Netto, George J., primary, Hoque, Mohammad O., primary, Hahn, Noah M., primary, McConkey, David J., primary, Baras, Alex S., primary, Drake, Charles G., primary, and Bivalacqua, Trinity J., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results